Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase

Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm constituting approximately 15% of newly diagnosed leukemia in adult patients. Development of tyrosine kinase inhibitors (TKIs) have dramatically improved outcomes in patients with chronic CML in chronic phase. However, adverse drug even...

Full description

Bibliographic Details
Main Authors: Yasuhiro Maeda, Atsushi Okamoto, Kenta Yamamoto, Go Eguchi, Yoshitaka Kanai
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Reports
Subjects:
chronic myeloid leukemia
tyrosine kinase inhibitor
adverse drug event
quality of life
second-generation tyrosine kinase inhibitor
nilotinib
Online Access:https://www.mdpi.com/2571-841X/2/4/25

Similar Items

Similar Items